Advertisement

The New Ways of Preventing and Treating Diabetes Mellitus

  • Peter FaschingEmail author
Chapter
Part of the Practical Issues in Geriatrics book series (PIG)

Abstract

Strategies in midlife to prevent development of diabetes mellitus, mostly T2D mellitus (T2D), and its negative late sequela for health are of imminent importance for the individual as well as for societies and health systems. Healthy lifestyle and body-weight control in midlife play a crucial role in avoiding or postponing manifestation of T2D since lifestyle interventions appear more sustainable concerning their preventive potential in comparison to different pharmaceutical approaches which—up to now—loose efficacy after stopping and wash out and bear the risk of side-effects. Therefore, for the time being, no drug is licensed for diabetes prevention. Nonetheless, novel medicamentous attempts for diabetes prevention and supporting healthy aging are under scientific investigation.

If T2D is diagnosed, adequate lifestyle modification and modern pharmaceutical strategies are required to safely control hyperglycemia in order to prevent severe acute and chronic complications, especially severe hypoglycemia and premature cardiovascular complications and death. Diabetes prevention has important implications for health policy.

Keywords

Type 2 diabetes mellitus prevention Weight management Frailty Metformin Pharmaceutical therapy Cardiovascular disease 

Abbreviations

BMI

Body mass index

CV

Cardiovascular

CVD

Cardiovascular disease

CVOT

Cardiovascular outcome trial

DPP

Diabetes Prevention Program [14]

DPP-4-I

Dipeptidyl-peptidase 4 inhibitors

DPPOS

Diabetes Prevention Program Outcome Study [15]

DPS

Diabetes Prevention Study [13]

GLP1-RA

Glucagon-like-peptide 1 receptor agonist

HbA1c

Glycosylated hemoglobin A1c

HR

Hazard ratio

IDF

International Diabetes Federation

sGLT2-I

Sodium-glucose-transporter 2 inhibitors

SSB

Sugar-sweetened beverages

T1D

Diabetes mellitus type 1

T2D

Diabetes mellitus type 2

References

  1. 1.
    International Diabetes Federation. IDF Diabetes Atlas 8th Edition. Available at: http://www.diabetesatlas.org/. Accessed 27 Dec 2017
  2. 2.
    Roeckl S, Brinks R, Baumert J et al (2017) All cause mortality in adults with and without type 2 diabetes: findings from the national health monitoring in Germany. BMJ Open Diab Res Care 5:e000451.  https://doi.org/10.1136/bmjdrc-2017-000451 CrossRefGoogle Scholar
  3. 3.
    Bierman AS, Tinetti ME (2016) Precision medicine to precision care: managing multimorbidity. Lancet 388:2721–2723CrossRefGoogle Scholar
  4. 4.
    American Diabetes Association (ADA) (2018) Prevention or delay of type 2 diabetes: standards of medical care in diabetes—2018. Diabetes Care 41(Suppl 1):S51–S54.  https://doi.org/10.2337/dc18-S005 CrossRefGoogle Scholar
  5. 5.
    American Diabetes Association (ADA) (2018) Approaches to glycemic treatment: standards of medical care in diabetes—2018. Diabetes Care 41(Suppl 1):S73–S85.  https://doi.org/10.2337/dc18-S008 CrossRefGoogle Scholar
  6. 6.
    Feldman AL, Griffin SJ, Al A et al (2017) Impact of weight maintenance and loss on diabetes risk and burden: a population-based study in 33,184 participants. BMC Public Health 17:170.  https://doi.org/10.1186/s12889-017-4081-6 CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    The Global BMI Mortality Collaboration (2016) Body-mass index and all-cause mortality: individual-participant-data-meta-analysis of 239 prospective studies in four continents. Lancet 388:776–786CrossRefGoogle Scholar
  8. 8.
    Gao F, Wang J, Shen H et al (2018) Impact of obesity on mortality in patients with diabetes: meta-analysis of 20 studies including 250,016 patients. J Diabetes Investig 9:44–54.  https://doi.org/10.1111/jdi.12677 CrossRefPubMedGoogle Scholar
  9. 9.
    Lee EY, Lee Y-h, Yi S-W, Shin S-A, Yi J-J (2017) BMI and all-cause mortality in normoglycemia, impaired fasting glucose, newly diagnosed diabetes, and prevalent diabetes: a cohort study. Diabetes Care 40:1026–1033CrossRefGoogle Scholar
  10. 10.
    American Diabetes Association (ADA) (2018) Classification and diagnosis of diabetes: standards of medical care in diabetes—2018. Diabetes Care 41(Suppl 1):S13–S27.  https://doi.org/10.2337/dc18-S002 CrossRefGoogle Scholar
  11. 11.
    Barry E, Roberts S, Oke J et al (2017) Efficacy and effectiveness of screen and treat policies in prevention of type 2 diabetes: systematic review and meta-analyis of screening tests and interventions. BMJ 356:i6538.  https://doi.org/10.1136/bmj.i6538 CrossRefPubMedGoogle Scholar
  12. 12.
    Lean MEJ, Leslie WS, Barnes AC et al (2018) Primary care-led weight management for remission of T2D (direct): an open label, cluster-randomised trial. Lancet 391(10120):541–551.  https://doi.org/10.1016/S0140-6736(17)33102-1 CrossRefPubMedGoogle Scholar
  13. 13.
    Tuomilehto J, Lindstrom J, Eriksson JG et al (2001) Prevention of T2D mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343–1350CrossRefGoogle Scholar
  14. 14.
    Knowler WC, Barrett-Connor E, Fowler SE et al (2002) Reduction in the incidence of type diabetes with lifestyle intervention or metformin. N Engl J Med 346:393–403CrossRefGoogle Scholar
  15. 15.
    Aroda VR, Knowler WC, Crandall JP et al (2017) For the diabetes prevention program research group. Metformin for diabetes prevention: insights gained from the diabetes prevention program/diabetes prevention program outcomes study. Diabetologia 60:1601–1611CrossRefGoogle Scholar
  16. 16.
    Le Roux CW, Astrup A, Fujioka K et al (2017) 3 years of liraglutide vs. placebo for T2Drisk reduction and weight management in individuals with prediabetes: a randomized, double-blind trial. Lancet 389:1399–1409CrossRefGoogle Scholar
  17. 17.
    Haw JS, Galaviz KI, Straus AN et al (2017) Long-term sustainability of diabetes prevention approaches. A systematic review and meta-analysis of randomized clinical trials. JAMA Intern Med 177:1808–1817.  https://doi.org/10.1001/jamainternmed.2017.6040 CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Canpbell JM, Bellman SM, Stephensen MD et al (2017) Metformin reduces all-cause mortality and diseases independent of its effect on diabetes control: a systematic review and meta-analysis. Ageing Res Rev 40:31–44.  https://doi.org/10.1016/j.arr.2017.08.003 CrossRefGoogle Scholar
  19. 19.
    Valencia WM, Palacio A, Tamariz L, Florez H (2017) Metformin and ageing: improving outcomes beyond glycaemic control. Diabetologia 60:1630–1638CrossRefGoogle Scholar
  20. 20.
    Aroda VR, Edelstein SL, Goldberg RB et al (2016) Long-term metformin use and vitamin B12 deficiency in the diabetes prevention program outcomes study. J Clin Endocrinol Metab 101:1754–1761CrossRefGoogle Scholar
  21. 21.
    Ocampo Chaparro JM (2013) Vitamin B12 deficit and development of geriatric syndromes. Colomb Med (Cali) 44:42–45e PMCID: PMC4002007Google Scholar
  22. 22.
    Brakedal B, Flones I, Reiter SF et al (2017) Glitazone use associated with reduced risk of Parkinson’s disease. Mov Disord 32(11):1594–1599.  https://doi.org/10.1002/mds.27128 CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Athauda D, Maclagan K, Skene SS et al (2017) Exenatide once weekly versus placebo in Parkinson’s disease: a randomized, double-blind, plazebo-controlled trial. Lancet 390:1664–1675CrossRefGoogle Scholar
  24. 24.
    Bae JP, Lage MJ, Mod NDR, Hoogwerf BJ (2016) Obesity and glycemic control in patients with diabetes mellitus: analysis of physician electronic health records in the US from 2009-2011. J Diab Compl 30:212–220CrossRefGoogle Scholar
  25. 25.
    Gummesson A, Nyman E, Knutsson M, Karpefors M (2017) Effect of weight reduction on hemoglobin A1c in weight loss trials of T2D patients. Diab Obes Metab 19:1295–1305.  https://doi.org/10.1111/dom.12971 CrossRefGoogle Scholar
  26. 26.
    Schauer PR, Deepak BL, Kirwan JP et al (2017) Bariatric surgery versus intensive medical therapy for diabetes—5-year outcomes. N Engl J Med 376:641–651CrossRefGoogle Scholar
  27. 27.
    Fougere B, Morley JE (2017) Weight loss is a major cause of frailty (editorial). J Nutr Health Aging 21(9):933–935CrossRefGoogle Scholar
  28. 28.
    Sinclair AJ, Abdelhafiz A, Dunning T et al (2017) On behalf of the expert working group. An international position statement on the management of frailty in diabetes mellitus: summary of recommendations 2017. J Frailty Aging. Available at: http://www.jfrailtyaging.com/all-issue.html?artcle=609
  29. 29.
    Morley JE, Anker SD (2017) Myopenia and precision (P4) medicine. J Cachexia Sarcopenia Muscle 8:857.  https://doi.org/10.1002/jcsm.12231 CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Holst C, Becker U, Jorgensen ME et al (2017) Alcohol drinking patterns and risk of diabetes: a cohort study of 70,551 men and women from the general Danish population. Diabetologia 60:1941–1950.  https://doi.org/10.1007/s00125-017-4359-3 CrossRefPubMedGoogle Scholar
  31. 31.
    Kondapally R, Seshasai S, Thompson A et al (2011) Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 364:829–841CrossRefGoogle Scholar
  32. 32.
    Schernthaner G, Lehmann R, Prazny M et al (2017) Translating recent results from the cardiovacular outcome trials into clinical practice: recommendations from the Central and Eastern European Diabetes Expert Group (CEEDEG). Cardiovasc Diabetol 16:137–149.  https://doi.org/10.1186/s12933-017-0622-7 CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Currie CJ, Holden SE, Jenkins-Jones S et al (2018) Impact of differing glucose-lowering regimens on the pattern of association between glucose control and survival. J Diab Obes Metab 20:821.  https://doi.org/10.1111/dom.13155 CrossRefGoogle Scholar
  34. 34.
    Sattar N, Preiss D, Murray HM et al (2010) Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 375:735–742CrossRefGoogle Scholar
  35. 35.
    Jones M, Tett S, Peeters GMEE et al (2017) New-onset diabetes after statin exposure in elderly women: the Australian Longitudinal Study on Women’s Health. Drugs Aging 34:203–209.  https://doi.org/10.1007/s40266-017-0435-0 CrossRefPubMedGoogle Scholar
  36. 36.
    Brown RT, Diaz-Ramirez LG, Boscardin WJ et al (2017) Functional impairment and decline in middle age: a cohort study. Ann Intern Med 167:761–768.  https://doi.org/10.7326/M17-0496 CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Sinharay R, Gong J, Barratt B et al (2018) Respiratory and cardiovascular responses to walking down a traffic-polluted road compared with walking in a traffic-free area in participants aged 60 years and older with chronic lung or heart disease and age-matched healthy controls: a randomised, cross-over study. Lancet 391:339–349.  https://doi.org/10.1016/s0140-6736(17)32643-0 CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Silver LD, Ng SW, Ryan-Ibarra S, Smith Taillie L et al (2017) Changes in prices, sales, consumer spending, and beverage consumption one year after tax on sugar-sweetened beverages in Berkeley, California, US: a before-and-after study. PLoS Med 14:e1002283.  https://doi.org/10.1371/journal.pmed.1002283 CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Luger M, Lafontan M, Bes-Rastrollo M et al (2017) Sugar-sweetened beverages and weight gain in children and adults: a systematic review from 2013 to 2015 and a comparison with previous studies. Obes Facts 10:674–693.  https://doi.org/10.1159/000484566 CrossRefGoogle Scholar
  40. 40.
    Kollannoor-Samuel G, Shbl FM, Hawley NL, Perez-Escamilla R (2017) Nutrition label use is associated with lower long-term diabetes risk in US adults. Am J Clin Nutr 105:1079–1085.  https://doi.org/10.3945/ajcn.116.145359 CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2019

Authors and Affiliations

  1. 1.5th Internal Department with Endocrinology, Rheumatology and Acute GeriatricsWilhelminenspital of the City of ViennaViennaAustria

Personalised recommendations